Neumora Therapeutics, Inc. 8-K

What Happened

• On March 30, 2026, Neumora Therapeutics, Inc. (NMRA) filed a Form 8-K (Item 2.02) to announce its financial results for the fourth quarter and full year ended December 31, 2025. The company furnished the full press release reporting those results as Exhibit 99.1 to the filing. The report is signed by CFO Michael Milligan.

Key Details

• Filing date: March 30, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Reporting period: fourth quarter and full year ended December 31, 2025.
• Exhibit included: 99.1 — Press Release dated March 30, 2026 (financial results).
• Administrative exhibit: Inline XBRL cover page (Exhibit 104); document signed by CFO Michael Milligan.

Why It Matters

• This 8-K signals that Neumora has publicly released its quarterly and annual earnings information (earnings, revenue and other quarterly results) for investors to review. The press release (Exhibit 99.1) contains the specific financial metrics and commentary needed to assess recent performance; shareholders and analysts should read that release for revenue, profit/loss, cash position, and any management commentary or guidance.